Drug Approval | January 20, 2022
Australia grants provisional registration for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
The stability is led by healthy demand in the domestic and emerging markets
Ind-Ra expects revenue growth of over 12% in 2022.
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
2022 is going to be the year of opportunities and innovations from the medical industry in India
Subscribe To Our Newsletter & Stay Updated
